AIDS and Behavior

, Volume 18, Issue 11, pp 2144–2155 | Cite as

Syringe Exchange in the United States: A National Level Economic Evaluation of Hypothetical Increases in Investment

  • Trang Quynh Nguyen
  • Brian W. Weir
  • Don C. Des Jarlais
  • Steven D. Pinkerton
  • David R. Holtgrave
Original Paper

Abstract

To examine whether increasing investment in needle/syringe exchange programs (NSPs) in the US would be cost-effective for HIV prevention, we modeled HIV incidence in hypothetical cases with higher NSP syringe supply than current levels, and estimated number of infections averted, cost per infection averted, treatment costs saved, and financial return on investment. We modified Pinkerton’s model, which was an adaptation of Kaplan’s simplified needle circulation theory model, to compare different syringe supply levels, account for syringes from non-NSP sources, and reflect reduction in syringe sharing and contamination. With an annual $10 to $50 million funding increase, 194–816 HIV infections would be averted (cost per infection averted $51,601–$61,302). Contrasted with HIV treatment cost savings alone, the rate of financial return on investment would be 7.58–6.38. Main and sensitivity analyses strongly suggest that it would be cost-saving for the US to invest in syringe exchange expansion.

Keywords

Cost-effectiveness Mathematical model Syringe exchange Injection drug use HIV 

Supplementary material

10461_2014_789_MOESM1_ESM.xls (38 kb)
Supplementary material 1 (XLS 38 kb)

References

  1. 1.
    Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. JAIDS J Acquir Immune Defic Syndr. 2010;53:124–30.CrossRefGoogle Scholar
  2. 2.
    Holtgrave DR, Wolitski RJ, Pals SL, Aidala A, Kidder DP, Vos D, et al. Cost–utility analysis of the housing and health intervention for homeless and unstably housed persons living with HIV. AIDS Behav. 2013;17:1626–31.PubMedCrossRefGoogle Scholar
  3. 3.
    Hutchinson AB, Patel P, Sansom SL, Farnham PG, Sullivan TJ, Bennett B, et al. Cost-effectiveness of pooled nucleic acid amplification testing for acute HIV infection after third-generation HIV antibody screening and rapid testing in the United States: a comparison of three public health settings. PLoS Med. 2010;7:e1000342.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Centers for Disease Control and Prevention. HIV cost-effectiveness. http://www.cdc.gov/hiv/prevention/ongoing/costeffectiveness. 2014. Retrieved 2014 Apr 19.
  5. 5.
    Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS One. 2011;6:e17502.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. 2010. http://www.whitehouse.gov/sites/default/files/uploads/NHAS.pdf.
  7. 7.
    Gold M, Gafni A, Nelligan P, Millson P. Needle exchange programs: an economic evaluation of a local experience. Can Med Assoc J. 1997;157:255–62.Google Scholar
  8. 8.
    Jacobs P, Calder P, Taylor M, Houston S, Saunders LD, Albert T. Cost effectiveness of Streetworks’ needle exchange program of Edmonton. Can J Public Health. 1999;90:168–71.PubMedGoogle Scholar
  9. 9.
    Laufer FN. Cost-effectiveness of syringe exchange as an HIV prevention strategy. JAIDS J Acquir Immune Defic Syndr. 2001;28:273–8.CrossRefGoogle Scholar
  10. 10.
    Cabasés JM, Sánchez E. Costs and effectiveness of a syringe distribution and needle exchange program for HIV prevention in a regional setting. Eur J Health Econ. 2003;4:203–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Kumaranayake L, Vickerman P, Walker D, Samoshkin S, Romantzov V, Emelyanova Z, et al. The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus. Addiction. 2004;99:1565–76.PubMedCrossRefGoogle Scholar
  12. 12.
    Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver’s supervised injection facility. Can Med Assoc J. 2008;179:1143–51.CrossRefGoogle Scholar
  13. 13.
    Pinkerton SD. Is Vancouver Canada’s supervised injection facility cost-saving? Addiction. 2010;105:1429–36.PubMedCrossRefGoogle Scholar
  14. 14.
    Wodak A, Cooney A. Effectiveness of sterile needle and syringe programmes. Int J Drug Policy. 2005;16S:S31–44.CrossRefGoogle Scholar
  15. 15.
    The Office of the Global AIDS Coordinator. PEPFAR blueprint: creating an AIDS-free generation. 2012. http://www.pepfar.gov/documents/organization/201386.pdf.
  16. 16.
    National Center for HIV/AIDS, Viral Hepatitis S and TP. Strategic Plan: Division of HIV/AIDS Prevention: 2011 through 2015. 2011. http://www.cdc.gov/hiv/pdf/policies_DHAP-strategic-plan.pdf.
  17. 17.
    Centers for Disease Control and Prevention. FY 2013 Full Year CR Operating Plan. http://www.cdc.gov/fmo/topic/Budget Information/appropriations_budget_form_pdf/FY2013_CDC_Full-Year_CR_Operating_Plan.pdf.
  18. 18.
    Health Omnibus Program Extensions of 1988 Act. http://history.nih.gov/research/downloads/PL100-607.pdf.
  19. 19.
    Barr S. Needle-exchange programs face new federal funding ban. Kaiser health news. 2011 Dec 21. http://www.kaiserhealthnews.org/stories/2011/December/21/needle-exchange-federal-funding.aspx.
  20. 20.
    Des Jarlais DC, Guardino V, Arasteh K, Mcknight C, Milliken J, Purchase D. Current state of syringe exchange in the known universe. 2010. Presentation at the National Syringe exchange Conference; 2010 Nov 17.Google Scholar
  21. 21.
    Tempalski B, Cooper HLF, Friedman SR, Des Jarlais DC, Brady JE, Gostnell K. Correlates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug. Int J Drug Policy. 2008;19(Suppl 1):S47–58.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Huo D, Ouellet LJ. Needle exchange and injection-related risk behaviors in Chicago: A longitudinal study. JAIDS J Acquir Immune Defic Syndr. 2007;45:108–14.CrossRefGoogle Scholar
  23. 23.
    Office of Applied Studies SA and MHSA. Injection drug use and related risk behaviors. The NSDUH Report. 2009 Oct 29. http://www.samhsa.gov/data/2k9/139/139IDU.htm.
  24. 24.
    Des Jarlais DC, Pinkerton SD, Hagan H, Guardino V, Feelemyer J, Cooper HLF, et al. 30 Years on selected issues in the prevention of HIV among persons who inject drugs. Adv Prev Med. 2013;2013:346372.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Kahn JG. Are NEPs cost-effective in preventing HIV infection? In: Lurie P, Reingold AL, Bowser B, Chen D, Foley J, Guydish J, et al., editors. The public health impact of needle exchange programs in the United States and abroad. San Francisco: University of California; 1993. p. 477–511.Google Scholar
  26. 26.
    Kaplan EH, Brandeau ML. AIDS policy modeling by example. AIDS. 1994;8(Suppl 1):S333–40.Google Scholar
  27. 27.
    Kaplan EH. Economic analysis of needle exchange. AIDS. 1995;9:1113–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet. 2001;357:1397–401.PubMedCrossRefGoogle Scholar
  29. 29.
    Shafer KP, Hahn JA, Lum PJ, Ocha K, Graves A, Moss A. Prevalence and correlates of HIV infection among young injection drug users in San Francisco. JAIDS J Acquir Immune Defic Syndr. 2002;31:422–31.CrossRefGoogle Scholar
  30. 30.
    Strathdee SA, Sherman SG. The role of sexual transmission of HIV infection among injection and non-injection drug users. J Urban Health. 2003;80:iii7–14.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Poulin C, Alary M, Bernier F, Carbonneau D, Boily M-C, Joly JR. Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae among at-risk women, young sex workers, and street youth attending community organizations in Quebec City, Canada. Sex Transm Dis. 2001;28:437–43.PubMedCrossRefGoogle Scholar
  32. 32.
    Des Jarlais DC, Arasteh K, McKnight C, Hagan H, Perlman DC, Friedman SR. Using hepatitis C virus and herpes simplex virus-2 to track HIV among injecting drug users in New York City. Drug Alcohol Depend. 2009;101:88–91.PubMedCrossRefGoogle Scholar
  33. 33.
    Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86:642–54.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Friedman SR, Tempalski B, Cooper HLF, Perlis TE, Keem M, Friedman R, et al. Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health. 2004;81:377–400.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Brady JE, Friedman SR, Cooper HLF, Flom PL, Tempalski B, Gostnell K. Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from to 2002. J Urban Health. 1992;2008(85):323–51.Google Scholar
  36. 36.
    Lansky A, Finlayson T, Johnson C, Holtzman D, Wejnert C, Mitsch A, et al. Estimating the number of injection drug users in the United States to calculate National Rates of HIV Infection. 2012. Poster presentation at the 2012 National Summit on HIV Diagnosis, Prevention and Access to Care. http://www.hivforum.org/storage/hivforum/documents/_2012NationalSummit_Posting/c_115_lansky.pdf.
  37. 37.
    Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733–45.PubMedCrossRefGoogle Scholar
  38. 38.
    Lurie P, Gorsky R, Jones TS, Shomphe L. An economic analysis of needle exchange and pharmacy-based programs to increase sterile syringe availability for injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:S126–32.PubMedCrossRefGoogle Scholar
  39. 39.
    Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano DD. Longitudinal patterns of drug injection behavior in the ALIVE study cohort 1988–2000: description and determinants. Am J Epidemiol. 2003;158:695–704.PubMedCrossRefGoogle Scholar
  40. 40.
    McCoy CB, Metsch LR, Chitwood DD, Shapshak P, Comerford ST. Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:S25–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Heimer R, Khoshnood K, Bigg D, Guydish J, Junge B. Syringe use and reuse: effects of syringe exchange programs in four cities. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:S37–44.PubMedCrossRefGoogle Scholar
  42. 42.
    Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Tovanabutra S, Robison V, Wongtrakul J, Sennum S, Suriyanon V, Kingkeow D, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. JAIDS J Acquir Immune Defic Syndr. 2002;29:275–83.CrossRefGoogle Scholar
  44. 44.
    Vickerman P, Hickman M, Rhodes T, Watts C. Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug users. JAIDS J Acquir Immune Defic Syndr. 2006;42:355–61.CrossRefGoogle Scholar
  45. 45.
    Vickerman P, Miners A, Williams J. Assessing the cost-effectiveness of interventions linked to needle and syringe programmes for injecting drug users: an economic modelling report Authors. 2008. http://www.nice.org.uk/nicemedia/pdf/NSPEconomicmodellingFullreportJune08.pdf. Retrieved 2012 Apr 3.
  46. 46.
    Bobashev GV, Zule WA, Morris RJ. Projecting sexual and injecting risks into future HIV outcomes with agent-based modeling. 2010. Poster presentation at the International AIDS Conference in Vienna, Austria, 2010. http://www.rti.org/pubs/bobashev_aids2010_poster.pdf.
  47. 47.
    National Research Council. Public financing and delivery of HIV/AIDS Care: securing the legacy of Ryan White. Washington, DC: The National Academies Press; 2005. http://www.iom.edu/Reports/2004/Public-Financing-and-Delivery-of-HIVAIDS-Care-Securing-the-Legacy-of-Ryan-White.aspx.

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Trang Quynh Nguyen
    • 1
    • 2
  • Brian W. Weir
    • 1
  • Don C. Des Jarlais
    • 3
  • Steven D. Pinkerton
    • 4
  • David R. Holtgrave
    • 1
  1. 1.Department of Health, Behavior and SocietyJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA
  2. 2.Institute for Studies of Society, Economy and EnvironmentHa NoiViet Nam
  3. 3.Beth Israel Medical CenterNew YorkUSA
  4. 4.Department of Psychiatry and Behavioral MedicineMedical College of WisconsinMilwaukeeUSA

Personalised recommendations